The product is disappearing into reorder rhythm: revenue is shifting from won-each-time to arriving-on-its-own, and the
The model's full reasoning — Q3 2022 call → NOWe need answer only YES or NO. Need evaluate transcript. Need determine if management describes growing share of revenue arrives without new selling event through reorders/refills/renewals/repeat purchases/usage-driven billing/aftermarket/consumable pull-through/customers' own routines, and that this self-arriving share has recently and visibly grown as proportion, grounded in observed current behavior, treating as changing quality of revenue. We need parse transcript. Company SI-BONE sells medical devices (implants) for SI joint fusion, trauma, deformity. Revenue from procedures using products. Not recurring revenue in typical sense. They sell implants per procedure. Repeat purchases? Surgeons perform procedures using products; active surgeon base grows. But is there "self-arriving revenue" without new selling event? They talk about surgeon adoption, active surgeons, procedure volumes. But each procedure requires selling? Maybe not. They mention "patient awareness initiatives" leading to surgeon referrals. But not reorders. Question asks: Does management describe that a growing share of revenue now arrives without a new selling event — through reorders, refills, renewals, repeat purchases, usage-driven billing, aftermarket or consumable pull-through, or customers' own standing routines — AND that this self-arriving share has recently and visibly grown as proportion? Need answer YES only if both halves present. Transcript: Laura talks about "surgeon adoption is one of the best leading indicators of long-term procedure demand." Active surgeon base growth. "We continue to experience a growing surgeon overlap across our various products." "higher surgeon utilization as synergistic surgeon base grows." "iFuse-TORQ continues to exceed expectations... record revenue." "Granite providing significant pull-through opportunity for overall portfolio, as some surgeons are using some combination of our product to at least two points of fixation... resulting in higher procedure average selling price." "Given positive experience with iFuse-Bedrock brand, we’ve seen surgeons expand the use of the product to stabilize the base of shorter multi-level construct..." This is about existing surgeons using more products per procedure, not self-arriving revenue. "Patient awareness initiatives... website traffic, patient engagement, surgeon referrals...
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
DUOT · Q4 2023 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, through reorders, renewals, etc., and that this has recently and visibly grown as a ...
QTRX · Q3 2023 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, like through reorders, consumables, etc., and that this share has recently grown.
CYBR · Q3 2021 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, like through renewals, and that this has recently grown as a proportion.